SCHEMBL2201678

SCHEMBL2201678

CC1CCc2nc(-c3cc(Cl)ccc3F)nc(O)c21

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 1/20 0.34
GRM2 Q14416 2/20 0.33
PRKD3 O94806 1/20 0.33
TGFBR1 P36897 1/20 0.33
PRKD1 Q15139 1/20 0.33
PRKD2 Q9BZL6 1/20 0.33
CHRM1 P11229 1/20 0.32
IDH2 P48735 1/20 0.31
TYMS P04818 1/20 0.31
HTR2B P41595 1/20 0.31
PDE4D Q08499 1/20 0.31
KDM4E B2RXH2 1/20 0.30
NPC1 O15118 1/20 0.30
LMNA P02545 1/20 0.30
NFKB1 P19838 1/20 0.30
CASP3 P42574 1/20 0.30
CDK9 P50750 1/20 0.30
RAB9A P51151 1/20 0.30
CDK5 Q00535 1/20 0.30
NFKB2 Q00653 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12426424 1.00 IDH1 (0.34) IDH1GRM2PRKD3TGFBR1PRKD1
SCHEMBL12426423 0.87 IDH1 (0.35) IDH1GRM2PRKD3TGFBR1PRKD1
SCHEMBL12426420 0.85 IDH1 (0.34) IDH1GRM2PRKD3TGFBR1PRKD1
SCHEMBL2200301 0.85 IDH1 (0.34) IDH1GRM2PRKD3TGFBR1PRKD1
SCHEMBL12426340 0.76 ACHE (0.43) CHRM1KDM4ELMNASMN1; SMN2
SCHEMBL2202293 0.76 SOS1 (0.44) CHRM1
SCHEMBL2199388 0.75 PRKD3 (0.34) IDH1GRM2PRKD3TGFBR1PRKD1
SCHEMBL12426422 0.74 TGFBR1 (0.41) PRKD3TGFBR1PRKD1PRKD2
SCHEMBL2201640 0.74 TGFBR1 (0.41) PRKD3TGFBR1PRKD1PRKD2
SCHEMBL12426215 0.73 TGFBR1 (0.51) TGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7977342-B2 HCV inhibiting bi-cyclic pyrimidines TIBOTEC-VIRCO VIROLOGY BVBA (BE) 2011-07-12 US disclosed
EP-1608631-A4 BI-CYCLIC PYRIMIDINE INHIBITORS OF TGF BETA SCIOS INC (US) 2008-08-20 EP disclosed
US-20070155716-A1 HCV INHIBITING BI-CYCLIC PYRIMIDINES TIBOTEC PHARMACEUTICALS LTD. (IE) 2007-07-05 US disclosed
EP-1799218-A1 HCV INHIBITING BI-CYCLIC PYRIMIDINES Tibotec Pharmaceuticals Ltd. (IE) 2007-06-27 EP disclosed
US-7223766-B2 Bi-cyclic pyrimidine inhibitors of TGFβ SCIOS, INC. (US) 2007-05-29 US disclosed
WO-2006035061-A1 HCV INHIBITING BI-CYCLIC PYRIMIDINES TIBOTEC PHARMACEUTICALS LTD. (IE) 2006-04-06 WO disclosed
EP-1608631-A2 BI-CYCLIC PYRIMIDINE INHIBITORS OF TGF BETA SCIOS INC. (US) 2005-12-28 EP disclosed
US-20050004143-A1 Bi-cyclic pyrimidine inhibitors of TGFbeta SCIOS, INC. 2005-01-06 US disclosed
WO-2004087056-A2 BI-CYCLIC PYRIMIDINE INHIBITORS OF TGFβ SCIOS INC. (US) 2004-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155716-A1 HCV INHIBITING BI-CYCLIC PYRIMIDINES UMPS, NUDT1, PNP IDH1 256/4885GRM2 4437/4885PRKD3 3048/4885
US-20050004143-A1 Bi-cyclic pyrimidine inhibitors of TGFbeta TYMP, TYMS, TGFBR1 IDH1 274/4885GRM2 3789/4885PRKD3 2090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.